Breaking News Instant updates and real-time market news.

PTLA

Portola Pharmaceuticals

$56.13

17.88 (46.75%)

16:25
06/23/17
06/23
16:25
06/23/17
16:25

Portola Pharmaceuticals hold a conference call

Management holds a conference call to discuss FDA approval of Bevyxxa (betrixaban) on June 23 at 4:30 pm. Webcast Link

  • 23

    Jun

  • 23

    Jun

  • 24

    Jun

PTLA Portola Pharmaceuticals
$56.13

17.88 (46.75%)

06/23/17
SBSH
06/23/17
NO CHANGE
SBSH
Buy
FDA precedent points to decision on Portola's betrixaban coming today, says Citi
After examining 22 cases over the last three years where a PDUFA date for a drug's approval fell on a weekend or holiday, Citi analyst Yigal Nochomovitz found a "strong bias" for the FDA to issue its decision prior to, rather than on or after, the deadline date. Given that the PDUFA date for Portola's betrixaban falls on Saturday, June 24, Nochomovitz said he expects the FDA to issue its decision on betrixaban today, June 23. The analyst, who sees a high probability of approval, keeps a Buy rating on Portola shares.
06/16/17
SBSH
06/16/17
NO CHANGE
Target $51
SBSH
Buy
Portola's interim cerdulatinib data 'look good,' says Citi
Citi analyst Yigal Nochomovitz says Portola Pharmaceuticals' interim cerdulatinib data in relapsed/refractory B-cell malignancies "look good" and provide upside not in his model. Success in developing cerdulatinib for this indication could provide additional upside for the shares, Nochomovitz tells investors in a research note. He keeps a Buy rating on Portola with a $51 price target.
04/19/17
SBSH
04/19/17
NO CHANGE
Target $51
SBSH
Buy
Citi says FDA analysis further supports Portola approval
Citi analyst Yigal Nochomovitz says his analysis of FDA precedence further supports approval of Portola Pharmaceuticals' novel blood thinner betrixaban. The FDA decision date is June 24. Two of the 29 drugs that were approved under Priority Review and no panel also missed their primary endpoints, Nochomovitz tells investors in a research note. He keeps a Buy rating on Portola with a $51 price target.
04/12/17
SBSH
04/12/17
NO CHANGE
Target $51
SBSH
Buy
Neurocrine approval reads positive for Portola, says Citi
Citi analyst Yigal Nochomovitz believes the approval of Neurocrine Biosciences' (NBIX) Ingrezza following a canceled advisory panel has a positive read-across to the ongoing FDA review for Portola Pharmaceuticals' (PTLA) betrixaban. The FDA had originally informed Portola to anticipate an advisory panel back in late December 2016, but in early February 2017 we learned the FDA was no longer requesting a panel, Nochomovitz tells investors in a research note. Ingrezza makes it four drugs out of four that got approved when a panel was canceled and there were no significant review issues identified by the FDA, the analyst adds, citing his analysis. The analyst notes he confirmed with Portola that no material issues were raised at the mid-cycle communication with the FDA on betrixaban. He keeps a Buy rating on Portola with a $51 price target.

TODAY'S FREE FLY STORIES

MLNX

Mellanox

$51.05

1 (2.00%)

, MRVL

Marvell

$21.59

1.3 (6.41%)

17:53
11/20/17
11/20
17:53
11/20/17
17:53
Hot Stocks
Starboard Value reports 9.8% stake in Mellanox, may seek talks »

Peter A. Feld, a…

MLNX

Mellanox

$51.05

1 (2.00%)

MRVL

Marvell

$21.59

1.3 (6.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 27

    Nov

  • 28

    Nov

  • 28

    Nov

  • 05

    Dec

  • 06

    Dec

CDXS

Codexis

17:46
11/20/17
11/20
17:46
11/20/17
17:46
Hot Stocks
Breaking Hot Stocks news story on Codexis »

Telemark Asset Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

T

AT&T

$34.64

0.13 (0.38%)

, TWX

Time Warner

$87.71

-1.01 (-1.14%)

17:45
11/20/17
11/20
17:45
11/20/17
17:45
Hot Stocks
AT&T CEO says giving up control of CNN is a 'non-starter' »

Says plenty of solutions…

T

AT&T

$34.64

0.13 (0.38%)

TWX

Time Warner

$87.71

-1.01 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

BBY

Best Buy

$56.35

0.52 (0.93%)

17:45
11/20/17
11/20
17:45
11/20/17
17:45
Conference/Events
Best Buy management to meet with SunTrust »

Group dinner to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 21

    Nov

T

AT&T

$34.64

0.13 (0.38%)

, TWX

Time Warner

$87.71

-1.01 (-1.14%)

17:43
11/20/17
11/20
17:43
11/20/17
17:43
Hot Stocks
AT&T CEO says DOJ suit 'defies logic' »

Says has offered…

T

AT&T

$34.64

0.13 (0.38%)

TWX

Time Warner

$87.71

-1.01 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

RELY

Real Industry

$0.52

0.1643 (45.92%)

17:38
11/20/17
11/20
17:38
11/20/17
17:38
Hot Stocks
Real Industry, Real Alloy receive court approval of 'first day' motions »

Real Industry announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RAVN

Raven

$34.65

0.85 (2.51%)

17:34
11/20/17
11/20
17:34
11/20/17
17:34
Earnings
Raven reports Q3 EPS 33c, consensus 23c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

ONTX

Onconova

$1.70

0.01 (0.59%)

17:34
11/20/17
11/20
17:34
11/20/17
17:34
Syndicate
Breaking Syndicate news story on Onconova »

Onconova files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

ONTX

Onconova

$1.70

0.01 (0.59%)

17:33
11/20/17
11/20
17:33
11/20/17
17:33
Syndicate
Breaking Syndicate news story on Onconova »

Onconova files $84.55M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

MLNX

Mellanox

$51.05

1 (2.00%)

17:31
11/20/17
11/20
17:31
11/20/17
17:31
Hot Stocks
Starboard Value reports 9.8% stake in Mellanox »

Starboard has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 05

    Dec

  • 06

    Dec

ASYS

Amtech Systems

$14.12

0.93 (7.05%)

, PANW

Palo Alto Networks

$142.53

-0.19 (-0.13%)

17:27
11/20/17
11/20
17:27
11/20/17
17:27
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: Amtech…

ASYS

Amtech Systems

$14.12

0.93 (7.05%)

PANW

Palo Alto Networks

$142.53

-0.19 (-0.13%)

URBN

Urban Outfitters

$28.27

0.37 (1.33%)

CLSN

Celsion

$2.14

0.14 (7.00%)

SNSS

Sunesis

$2.87

0.01 (0.35%)

HAIN

Hain Celestial

$40.89

1.05 (2.64%)

NSRGY

Nestle

$85.14

0.03 (0.04%)

A

Agilent

$69.96

1.17 (1.70%)

BECN

Beacon Roofing

$56.28

0.65 (1.17%)

INTU

Intuit

$157.78

1.23 (0.79%)

SNCR

Synchronoss

$11.14

0.76 (7.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 30

    Nov

  • 11

    Dec

  • 11

    Dec

  • 17

    Jan

  • 17

    Jan

SNGX

Soligenix

$2.24

0.02 (0.90%)

17:23
11/20/17
11/20
17:23
11/20/17
17:23
Syndicate
Breaking Syndicate news story on Soligenix »

Soligenix files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTIB

CTI Industries

$3.56

-0.269 (-7.03%)

17:23
11/20/17
11/20
17:23
11/20/17
17:23
Hot Stocks
CTI Industries names Frank Cesario CFO »

CTI Industries announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEDG

SolarEdge

$38.90

1.35 (3.60%)

17:22
11/20/17
11/20
17:22
11/20/17
17:22
Hot Stocks
SolarEdge chairman, CEO Sella diagnosed with colon cancer »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 28

    Nov

  • 29

    Nov

STLY

Stanley Furniture

$0.93

0.0349 (3.92%)

17:20
11/20/17
11/20
17:20
11/20/17
17:20
Hot Stocks
Breaking Hot Stocks news story on Stanley Furniture »

Stanley Furniture trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLAD

Gladstone Capital

$9.76

-0.02 (-0.20%)

17:09
11/20/17
11/20
17:09
11/20/17
17:09
Earnings
Gladstone Capital reports Q4 NII 21c, consensus 21c »

Reports NAV per share…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

T

AT&T

$34.64

0.13 (0.38%)

, TWX

Time Warner

$87.71

-1.01 (-1.14%)

17:07
11/20/17
11/20
17:07
11/20/17
17:07
Hot Stocks
Breaking Hot Stocks news story on AT&T, Time Warner »

Department of Justice…

T

AT&T

$34.64

0.13 (0.38%)

TWX

Time Warner

$87.71

-1.01 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

LMT

Lockheed Martin

$314.65

4.95 (1.60%)

17:07
11/20/17
11/20
17:07
11/20/17
17:07
Hot Stocks
Lockheed Martin awarded $122.3M U.S. Navy contract »

ockheed Martin Rotary and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

ZTO

ZTO Express

$17.00

0.17 (1.01%)

17:02
11/20/17
11/20
17:02
11/20/17
17:02
Earnings
Breaking Earnings news story on ZTO Express »

ZTO Express sees Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

MSG

Madison Square Garden

$215.00

-3.46 (-1.58%)

17:01
11/20/17
11/20
17:01
11/20/17
17:01
Hot Stocks
Madison Square Garden acquires Obscura Digital, terms not disclosed »

The Madison Square Garden…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZTO

ZTO Express

$17.00

0.17 (1.01%)

17:01
11/20/17
11/20
17:01
11/20/17
17:01
Earnings
ZTO Express reports Q3 EPS 15c, consensus 15c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

VICL

Vical

$1.98

0.04 (2.06%)

16:59
11/20/17
11/20
16:59
11/20/17
16:59
Hot Stocks
Breaking Hot Stocks news story on Vical »

Armistice Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BECN

Beacon Roofing

$56.28

0.65 (1.17%)

16:57
11/20/17
11/20
16:57
11/20/17
16:57
Earnings
Beacon Roofing sees FY18 adjusted EPS $2.95-$3.25, consensus $2.57 »

Sees FY18 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

ABC

AmerisourceBergen

$77.46

-1.38 (-1.75%)

16:56
11/20/17
11/20
16:56
11/20/17
16:56
Earnings
AmerisourceBergen sees FY18 revenue up 8%-11% following H.D. Smith acquisition »

Consensus $164.76B. Based…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 29

    Nov

ABC

AmerisourceBergen

$77.46

-1.38 (-1.75%)

16:53
11/20/17
11/20
16:53
11/20/17
16:53
Hot Stocks
AmerisourceBergen to acquire H.D. Smith for $815M in cash »

AmerisourceBergen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 29

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.